Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of venlafaxine in Japanese pediatric patients with MDD or PDD
2024-000605-33Phase 3
- Sponsor
- Viatris
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venlafaxine in major depressive disorder (MDD) and persistent depressive disorder (PDD), sponsored by Viatris. Primary endpoint: Safety endpoints.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on 2024-000605-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000605-33.